Micro-invased medical split, the latest news announced

Pharmaceutical Network January 14 - Micro-invased medical robots to be listed January 12, according to China Electronic News, Shanghai minimally invascope medical robots (Group) Co., Ltd. has signed a listing counseling agreement with COFCO, the proposed listing of the board.
follows a December announcement that Micro-Invasive Healthcare was considering a possible spin-off of the company's non-whowicial subsidiary, Micro-Invasive Medical Robotics, and its shares listed independently on an accredited stock exchange.
, minimally invascopic medical robots were established in 2014 and cover the five main tracks of laparoscopy, orthopaedics, vascular intervention, natural cavity, and persepassion, according to the official website.
the company reported a net loss of $2.309 million in the first half of last year, according to the company's 2020 semi-annual report.
's current three flagship products of minimally invasable medical robots, eye ™DFVision™ 3D electronic laparoscopy, Tumei™Toumai™ laparoscopic surgery robot, Hongxuan ™Skywalker™ joint replacement surgery robot, have entered the National Drug Administration innovative medical device green channel.
it is understood that the current domestic orthopaedic surgery robot enterprise Tianzhihang has successfully landed on the board, become the "domestic surgical robot" the first unit.
Micro-Invased Medical is the second surgical robot company to land on the board after Tianzhihang.
, China's surgical robot industry has maintained a high growth rate in recent years, with the market size of the surgical robot industry reaching 619 million yuan in 2019, up 40.6% year-on-year, according to the consulting data.
proportion of domestic surgical robots increased from 20.58 percent in 2016 to 52.16 percent in 2019.
But there are still many problems to be solved in the field of surgical robots, China Industrial Information Network analysis, surgical robot prices are higher, and the cost of surgery basically need to take care of themselves, has not been included in health insurance, the prevalence and uivity in China is still low.
addition, the development of surgical robots in China still faces adverse factors such as the price threshold for surgical robots to enter medical institutions, the high cost of robot surgery, and the monopoly of intellectual property rights restricting the research and development cost of domestic surgical robots.
Micro-Invasive Medical has repeatedly dismantled the spin-off of micro-invasive medical robots, and on January 6, Micro-Invasive Medical announced that it had indicated that eligible shareholders could subscribe for one reserved share for every 200 shares held at 4:30 p.m. on the record date (January 19).
understood that on November 9, MicroInvascope Medical announced that it proposed to spin off its subsidiary MicroPortCardioFlowMedtech Corporation, a subsidiary of the company, which is listed independently on the Main Board of the Stock Exchange.
micro-invasive heart is mainly engaged in research and development, manufacturing and sales of treatment valve heart disease equipment business.
according to minimally invasive medical semi-annual report 2020, its heart valve product, VitaFlow catheter aortic valve system, was certified and licensed by the State Drug Administration in July 2019 and completed its first implantation after its launch on August 28, 2019.
2020 semi-annual report shows that the number of hospitals covered by the above-mentioned system has increased rapidly since its launch, with some hospitals or departments being developed exclusively by Minimally Invascopic Medical.
addition, in 2019 micro-invasional medical also split the aortic and exovascular intervention business - subsidiary Heartline Medical listed on the Tablet.
according to the prospector, cardiovascular medicine in China's aortic vascular intervention medical device field ranked first.
2016-18, Heartline Healthcare's revenue was approximately $1.25 billion, $1.65 billion and $2.31 billion, respectively, with a compound growth rate of 136%, and its aortic stent sales revenue as a percentage of total revenue has been around 80%.
For the reasons for the spin-off listing, for example, on November 9 last year, Micro-Invasion Healthcare announced that the reasons for proposing a spin-off of Micro-Invascope were as follows: (a) the value of the spin-off company, which is in the rapid growth phase, would be realized under the separate platform of the spin-off business. (b) separating the spin-off business from the retention business so that shareholders and investors can assess the strategy, success factors, functional risks, risks and returns of the spin-off group and the group, respectively;
Spin-off would provide the spin-off group with direct access to capital markets for equity and/or debt financing to finance the continued sale and marketing of its products, (d) enhance the image of the spin-off group and increase its ability to attract investors to invest in the spin-off group, (e) increase the operational and financial transparency of the spin-off company, improve corporate governance of the spin-off company, and (f) enable the retention group and the spin-off group to develop, strategically plan and better allocate resources to their respective businesses.